HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Effects of etravirine versus placebo on health-related quality of life in treatment-experienced HIV patients as measured by the functional assessment of human immunodeficiency virus infection (FAHI) questionnaire in the DUET trials.

AbstractPURPOSE:
To study the effects of etravirine versus placebo on the health-related quality of life (HRQL) of HIV-infected patients.
METHOD:
HRQL of HIV-infected patients was measured using the Functional Assessment of Human Immunodeficiency Virus Infection (FAHI) questionnaire in two identically designed phase III clinical trials investigating efficacy and safety of etravirine as part of highly active antiretroviral therapy. Pooled analyses of covariance, adjusted for treatment group, baseline FAHI score, CD4 cell count, viral load, and enfuvirtide use helped investigate changes in FAHI scores between baseline and Week 24 in etravirine-treated (n = 599) and placebo-treated (n = 604) subjects. Responder analyses were also conducted.
RESULTS:
Significant improvements with etravirine treatment were observed for FAHI physical, functional, emotional, and total scores (P < .001). These improvements were greater and statistically different from those with placebo (.013 <P < .033). Baseline FAHI scores were significantly linked to changes in FAHI scores, and CD4 cell count had a significant but small effect on changes in FAHI total and social scores. Predicted percentages of responders were slightly but not significantly higher for etravirine than for placebo (24%-42% vs 23%-40%, respectively, for FAHI total score).
CONCLUSION:
At 24 weeks, etravirine in combination with other antiretroviral agents demonstrated incremental improvements in HRQL compared to placebo.
AuthorsDavid Cella, Hélène Gilet, Muriel Viala-Danten, Katrien Peeters, Dominique Dubois, Silas Martin
JournalHIV clinical trials (HIV Clin Trials) 2010 Jan-Feb Vol. 11 Issue 1 Pg. 18-27 ISSN: 1528-4336 [Print] United States
PMID20400408 (Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Anti-HIV Agents
  • Pyridazines
  • etravirine
Topics
  • Adolescent
  • Adult
  • Aged
  • Anti-HIV Agents (administration & dosage)
  • Antiretroviral Therapy, Highly Active (methods)
  • CD4 Lymphocyte Count
  • Double-Blind Method
  • Female
  • HIV (immunology)
  • HIV Infections (drug therapy, immunology, virology)
  • Humans
  • Male
  • Middle Aged
  • Pyridazines (administration & dosage)
  • Quality of Life
  • Surveys and Questionnaires
  • Viral Load
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: